The Future of BioPharma blog provides timely coverage of news that directly impacts the business strategies of the biotech, pharmaceutical and medical device industries. In addition to news coverage, the Future of BioPharma blog features live event coverage from IIR's Biopharmaceutical and Healthcare division.
With the new healthcare reform, there is an option for biosimilars to be approved for US use. However, due to the complexities of making the similar drug, the FDA will be more rigorous with their approval process, assuring that the generics and original drugs genetic structures are the same. Read the full article at Fierce Pharma here.
Share this article with your social network, just click below to share now!
No comments :
Post a Comment